Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) Operating Income (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Operating Income for 8 consecutive years, with -$65.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Income fell 2.67% year-over-year to -$65.6 million, compared with a TTM value of -$290.0 million through Sep 2025, down 47.63%, and an annual FY2024 reading of -$209.9 million, down 10.49% over the prior year.
  • Operating Income was -$65.6 million for Q3 2025 at Bicycle Therapeutics, up from -$86.6 million in the prior quarter.
  • Across five years, Operating Income topped out at -$14.3 million in Q3 2021 and bottomed at -$86.6 million in Q2 2025.
  • Average Operating Income over 5 years is -$42.3 million, with a median of -$41.8 million recorded in 2023.
  • The sharpest move saw Operating Income rose 24.13% in 2024, then crashed 121.35% in 2025.
  • Year by year, Operating Income stood at -$18.0 million in 2021, then crashed by 78.71% to -$32.2 million in 2022, then crashed by 68.37% to -$54.2 million in 2023, then fell by 24.76% to -$67.7 million in 2024, then increased by 3.12% to -$65.6 million in 2025.
  • Business Quant data shows Operating Income for BCYC at -$65.6 million in Q3 2025, -$86.6 million in Q2 2025, and -$70.2 million in Q1 2025.